Remission of persistent childhood asthma: Early predictors of adult outcomes.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
05 2019
Historique:
received: 04 06 2018
revised: 20 08 2018
accepted: 21 09 2018
pubmed: 18 11 2018
medline: 12 5 2020
entrez: 17 11 2018
Statut: ppublish

Résumé

Few data exist on the predictors of asthma remission by early adulthood in North America. The predictors of adult asthma remission were determined in a multiethnic population of patients with mild-to-moderate persistent childhood asthma. Asthma remission in early adulthood was measured by using 2 definitions: a clinical and a strict definition. Both included normal lung function and the absence of symptoms, exacerbations, and medication use. The strict definition also included normal airways responsiveness. Predictors were identified from 23 baseline measures by using multivariate logistic regression. The probability of remission was modeled by using decision tree analysis. In 879 subjects the mean ± SD baseline age was 8.8 ± 2.1 years, 59.4% were male, and 68.7% were white. By adulthood, 229 (26.0%) of 879 participants were in clinical remission, and 111 (15.0%) of 741 participants were in strict remission. The degree of FEV A considerable minority of patients with persistent childhood asthma will have disease remission by adulthood. Clinical prognostic indicators of asthma remission, including baseline lung function, can be seen from an early age.

Sections du résumé

BACKGROUND
Few data exist on the predictors of asthma remission by early adulthood in North America.
OBJECTIVE
The predictors of adult asthma remission were determined in a multiethnic population of patients with mild-to-moderate persistent childhood asthma.
METHODS
Asthma remission in early adulthood was measured by using 2 definitions: a clinical and a strict definition. Both included normal lung function and the absence of symptoms, exacerbations, and medication use. The strict definition also included normal airways responsiveness. Predictors were identified from 23 baseline measures by using multivariate logistic regression. The probability of remission was modeled by using decision tree analysis.
RESULTS
In 879 subjects the mean ± SD baseline age was 8.8 ± 2.1 years, 59.4% were male, and 68.7% were white. By adulthood, 229 (26.0%) of 879 participants were in clinical remission, and 111 (15.0%) of 741 participants were in strict remission. The degree of FEV
CONCLUSION
A considerable minority of patients with persistent childhood asthma will have disease remission by adulthood. Clinical prognostic indicators of asthma remission, including baseline lung function, can be seen from an early age.

Identifiants

pubmed: 30445065
pii: S0091-6749(18)31590-2
doi: 10.1016/j.jaci.2018.09.038
pmc: PMC7061344
mid: NIHMS1564699
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1752-1759.e6

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL129935
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025780
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007306
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL065899
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075417
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075416
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075419
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000051
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075408
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075232
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075415
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075407
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR002719
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075420
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000154
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000036
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL075409
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HR16044
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007427
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127332
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Références

J Allergy Clin Immunol. 2014 Jun;133(6):1572-8.e3
pubmed: 24495434
Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1490-5
pubmed: 8256889
Allergy Asthma Proc. 2018 Jul 1;39(4):281-288
pubmed: 30095393
Am J Respir Crit Care Med. 2000 Jan;161(1):309-29
pubmed: 10619836
J Stat Softw. 2017 Aug;79:
pubmed: 30686944
Am J Physiol Lung Cell Mol Physiol. 2001 Feb;280(2):L229-38
pubmed: 11159001
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Allergy Clin Immunol. 2010 Feb;125(2):359-366.e3
pubmed: 20159245
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
Lancet. 2008 Sep 20;372(9643):1058-64
pubmed: 18805334
Am J Respir Crit Care Med. 1997 Apr;155(4):1267-72
pubmed: 9105065
N Engl J Med. 2006 May 11;354(19):1998-2005
pubmed: 16687712
Am J Respir Crit Care Med. 2014 Jun 1;189(11):1316-27
pubmed: 24881937
Thorax. 2004 Nov;59(11):925-9
pubmed: 15516465
N Engl J Med. 2016 May 12;374(19):1842-1852
pubmed: 27168434
N Engl J Med. 2006 May 11;354(19):1985-97
pubmed: 16687711
Pediatrics. 2013 Aug;132(2):e435-42
pubmed: 23897917
Arch Dis Child. 1977 Aug;52(8):613-9
pubmed: 921306
J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138
pubmed: 17983880
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596433
Thorax. 2011 Jun;66(6):508-13
pubmed: 21450787
N Engl J Med. 2000 Oct 12;343(15):1054-63
pubmed: 11027739
J Pediatr. 2009 May;154(5):682-7
pubmed: 19167726
Am J Respir Crit Care Med. 2017 Dec 1;196(11):1463-1472
pubmed: 29192835
J Allergy Clin Immunol. 2015 Oct;136(4):829-36; quiz 837
pubmed: 26449797
N Engl J Med. 2003 Oct 9;349(15):1414-22
pubmed: 14534334
Control Clin Trials. 1999 Feb;20(1):91-120
pubmed: 10027502

Auteurs

Alberta L Wang (AL)

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

Soma Datta (S)

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

Scott T Weiss (ST)

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

Kelan G Tantisira (KG)

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: rekgt@channing.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH